	US 11,717,513 B2
	Mirabegron for the treatment of retinal diseases
Valérie Fontaine, Cachan (FR); Cécile Vidal, Joinville-le-Pont (FR); and José-Alain Sahel, Paris (FR)
Assigned to SORBONNE UNIVERSITE, Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR)
Appl. No. 15/777,078
Filed by SORBONNE UNIVERSITE, Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR)
PCT Filed Nov. 17, 2016, PCT No. PCT/FR2016/052981 § 371(c)(1), (2) Date May 17, 2018, PCT Pub. No. WO2017/085407, PCT Pub. Date May 26, 2017.
Claims priority of application No. 1561067 (FR), filed on Nov. 17, 2015.
Prior Publication US 2018/0353482 A1, Dec. 13, 2018
Int. Cl. A61K 31/426 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01)

CPC A61K 31/426 (2013.01) [A61K 9/0048 (2013.01); A61K 9/0053 (2013.01); A61P 27/02 (2018.01)]

5 Claims

1. A method for treating a retinal disease in a subject in need thereof, comprising administering to the subject mirabegron or a pharmaceutically acceptable salt or solvate thereof, wherein said retinal disease is age-related macular degeneration, Stargardt disease or pigmentary retinitis.